UNIGE document Scientific Article
previous document  unige:89956  next document
add to browser collection

Glatiramer acetate treatment negatively regulates type I interferon signaling

Prod'homme, Thomas
Schulze-Topphoff, Ulf
Spencer, Collin M
Weber, Martin S
Patarroyo, Juan C
Zamvil, Scott S
Published in Neurology: Neuroimmunology & Neuroinflammation. 2015, vol. 2, no. 6, p. e179
Abstract Glatiramer acetate (GA; Copaxone), a disease-modifying therapy for multiple sclerosis (MS), promotes development of anti-inflammatory (M2, type II) monocytes that can direct differentiation of regulatory T cells. We investigated the innate immune signaling pathways that participate in GA-mediated M2 monocyte polarization.
PMID: 26601118
Full text
Article (Published version) (983 Kb) - document accessible for UNIGE members only Limited access to UNIGE
Research group Scléroses en plaques, neuroimmunologie, encéphalite autoimmune expérimentale (843)
(ISO format)
MOLNARFI, Nicolas et al. Glatiramer acetate treatment negatively regulates type I interferon signaling. In: Neurology: Neuroimmunology & Neuroinflammation, 2015, vol. 2, n° 6, p. e179. https://archive-ouverte.unige.ch/unige:89956

48 hits

0 download


Deposited on : 2016-12-07

Export document
Format :
Citation style :